[Prevalence of hepatitis C virus in poly-transfused patients with hematologic and oncologic diseases]. / Prävalenz des Hepatitis-C-Virus bei polytransfundierten Patienten mit hämatologischen und onkologischen Erkrankungen.
Infusionsther Transfusionsmed
; 19(1): 19-22, 1992 Feb.
Article
em De
| MEDLINE
| ID: mdl-1376184
ABSTRACT
Patients with hematological and oncological diseases often require intensive, supportive hematotherapy due to the underlying disease or chemo-/radiotherapy. As a consequence, they had an increased transfusion-associated risk of hepatitis C virus infections (non-A, non-B-posttransfusion hepatitis) until 1989-1990, when specific and sensitive HCV antibody tests became available. This is confirmed by our study of 'first' and 'second' generation (1.0 and 2.0) anti-HCV EIAs against structural and non-structural (NS) antigen-determinants. Ten of 101 patients (10.9%) were anti-HCV positive in 2.0 tests. HCV antibodies were detected more often by 2.0 EIAs and the new HCV-immunoblot (4-RIBA), than by 1.0 EIAs. In this respect, the patients' serological HCV profile differs from that of healthy blood donors, which display a prevalence of NS-antibodies.
Buscar no Google
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Transfusão de Sangue
/
Hepatite C
/
Doenças Hematológicas
/
Neoplasias
Tipo de estudo:
Diagnostic_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
De
Revista:
Infusionsther Transfusionsmed
Assunto da revista:
CIENCIAS DA NUTRICAO
Ano de publicação:
1992
Tipo de documento:
Article